1. |
Rosbe KW, Prazma J, Petrusz P, et al. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck [J]. Otolaryngol Head Neck Surg, 1995; 113(5)∶541.
|
2. |
Fujimoto H, Ando Y, Yamashita T, et al. Nitric oxide synthase activity in human lung cancer [J]. Jpn J Cancer Res, 1997; 88(12)∶1190.
|
3. |
Thomsen LL, Miles DW, Happerfield L, et al. Nitric oxide synthase activity in human breast cancer [J]. Br J Cancer, 1995; 72(1)∶41.
|
4. |
Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth [J]. Proc Natl Acad Sci USA, 1995; 92(10)∶4392.
|
5. |
Yamamoto T, Terada N, Seiyama A, et al. Increase in experimental pulmonary metastasis in mice by Larginine under inhibition of nitric oxide production by NGnitroLarginine methyl ester [J]. Int J Cancer, 1998; 75(1)∶140.
|
6. |
Dong SM, Kim KM, Kim SY, et al. Frequent somatic mutations in serine/threonine kinase 11/PeutzJeghers syndrome gene in leftsided colon cancer [J]. Cancer Res, 1998; 58(17)∶3787.
|
7. |
Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer [J]. J Natl Cancer Inst, 1998; 90(8)∶587.
|
8. |
Teruo I, Masahiko H, Keiko K, et al. NGnitroLarginine methyl ester inbibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model [J]. Jpn J Cancer Rev, 1997; 88(6)∶801.
|
9. |
Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors [J]. Cancer Metastasis Rev, 1998; 17(1)∶91.
|
10. |
Takahashi M, Fukuda K, Ohata T, et al. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane [J]. Cancer Res. 1997; 57(7)∶1233.
|
11. |
Tschugguel W, Knogler W, Czerwenka K, et al. Presence of endothelial calciumdependent nitric oxide synthase in breast apocrine metaplasia [J]. Br J Cancer, 1996; 74(9)∶1423.
|
12. |
Jiang H, Stewart CA, Leu RW. Tumorderived factor synergizes with IFNgamma and LPS, IL2 or TNFalpha to promote macrophage synthesis of TNFalpha and TNF receptors for autocrine induction of nitric oxide synthase and enhanced nitric oxidemediated tumor cytotoxicity [J]. Immunobiology, 1995; 192(5)∶321.
|
13. |
Li LM, Killoun RG, Adams J, et al. Role of nitric oxide in lysis of tumor cells by cytokineactivate endothelial cells [J]. Cancer Res, 1991; 51(5)∶531.
|
14. |
Yasushi Y, Akiva M, Takash R, et al. p27 in human lung cancer: differential in smallcell and nonsmallcell carcinoma [J]. Cancer Res, 1998; 58(10)∶1042.
|
15. |
Zhang J, Dawson VL, Dawson TM, et al. Nitric oxide activation of poly (ADPribose) synthetase in neurotoxicity [J]. Science, 1994; 263(8)∶687.
|
16. |
Sagar SM, Singh G, Hodson DI, et al. Nitric oxide and anticancer therapy [J]. Cancer Treat Rev, 1995; 21(2)∶159.
|
17. |
Ho YS, Wang YJ, Lin JK. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells [J]. Mol Carcinog, 1996; 16(1)∶20.
|
18. |
Harrison DJ, Howie SEM, Wyllie AH, et al. Lymphocyte death, p53 and the problem of the “undead” cell. In: Kroemer G, Martinez AC, ed. Apoptosis in immunology [M]. Berlin: SpringVerlag, 1995∶123-128.
|